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Introduction
It has been recently established that regardless of phenotypic variability between different cancer types, perturbation of a limited number of genetic elements is sufficient to induce transformation in different human cell types 1 . Experimentally, it was demonstrated that activation of RAS and telomerase (TERT), along with inactivation of the tumour suppressor proteins P53 and Retinoblastoma protein (RB) can immortalize a variety of human cell types, which can subsequently transform to a tumourigenic state in response to inhibition of protein phosphatase 2A (PP2A) 1, 2 . Various independent studies have shown that inhibition of PP2A activity is a pre-requisite for human cell transformation 1, [3] [4] [5] . Therefore, understanding the mechanisms by which PP2A is inhibited in cancer cells is vital for developing new anti-cancer therapies.
Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) is a recently identified oncogene, which has been demonstrated to inhibit the endogenous tumour suppressive activity of PP2A in cancer cells 6 . Several layers of evidence, both from us and others, have shown CIP2A to be required for malignant cell growth and in vivo tumour formation [7] [8] [9] [10] [11] [12] . In addition, the prognostic role of CIP2A has been demonstrated in several human tumours 8, [11] [12] [13] . Moreover, since CIP2A overexpression has been observed at a high frequency in most human cancers studied so far 6-9, [13] [14] [15] [16] [17] [18] [19] [20] , identification of mechanisms regulating its expression in human cancers becomes important to address.
Although several transcription factors like MYC 8 , ETS1
17 , E2F1 9 and ATF2 19 have been identified as positive regulators of CIP2A in various carcinomas, factors influencing CIP2A expression in non-hematopoietic mesenchymal cells or sarcomas, are yet to be discovered. Notably, CIP2A amplification has been observed in soft-tissue sarcomas 21 . In addition, since CIP2A was identified using HT1080 (human fibrosarcoma cell line) cell extracts 6 this cell line was selected to dissect the mechanisms for high CIP2A expression in sarcomas. Since p38, ERK and JNK signalling pathways are commonly perturbed in cancers, we assessed the role of these pathways in CIP2A expression in HT1080 cells. To this end, respective small molecule kinase inhibitors, namely SB203580 (p38 pathway inhibitor), PD98059 (MEK pathway inhibitor) and SP600125 (JNK pathway inhibitor) were used to inhibit signalling through these pathways in HT1080 cells.
Material and methods
Chemicals SP600125 was purchased from Calbiochem (Cat No. -420119, Merck-Millipore CAS 129-56-6, San Diego, CA) and stocked as a 20 mM solution in DMSO. PD98059 was purchased from Calbiochem (Cat No. -513000, Merck-Millipore, San Diego, CA) and stocked as 40 mM stock in DMSO. SB203580 was purchased from Calbiochem (Cat No. -559389, Merck-Millipore, San Diego, CA) and stocked as 20 mM.
RNAi
The siRNAs to inhibit CIP2A expression were obtained from Eurofins MWG operon (Ebersberg, Germany). Either of the following double-stranded oligonucleotides was transiently transfected into HT1080 cell line as CIP2A siRNAs: CIP2A.1, 5´-CUGUGGU-UGUGUUUGCACUTT-3´, and CIP2A.2, 5´-ACCAUUGAUAUC-CUUAGAATT-3´. As a control, a scrambled siRNA with the sequence 5´-UAACAAUGAGAGCACGGCTT-3´ was used instead. HP-validated siRNAs for human JNK1 and JNK2 were purchased from Qiagen Sciences (Germantown, MD). Either of the following oligonucleotides were transiently transfected into HT1080 at 30%-50% confluency in a six-well plate were transfected with the siRNA in antibiotic free medium using RNAiMAX Reagent (Invitrogen, Carlsbad, CA), according to the manufacturer's instructions.
Immunoblotting
Proteins were extracted in hot Laemmli sample buffer and subjected to immunoblot analysis. Thirty micrograms of total protein extracts was separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Bio-Rad Laboratories, Helsinki, Finland) and transferred to nitrocellulose membranes (Thermo Scientific Pierce Protein Biology Products, Rockford, USA). Membranes were blocked with 5% non-fat milk in Tris-buffered saline (TBS; 20 mM Trizma Base and 150 mM NaCl dissolved in distilled water and adjusted with HCl to pH 7.5) containing 0.1%-NP40 (Igepal Ca-630; Sigma-Aldrich) 8 . Cell culture HT1080 cells originally were obtained from ATCC and were cultured in DMEM (Gibco) supplemented with 10% (v/v) fetal calf serum (FCS), 2 mM glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin (Bio-Whittaker Europe, Verviers, Belgium).
mRNA analysis
Total mRNA was extracted from cells using the RNeasy kit (Qiagen, Valencia, CA) and converted to cDNA by using the M-MLV Reverse Transcriptase, RNase H Minus, Point Mutant cDNA synthesis kit (Promega Corporation, Madison, WI). cDNAs were subjected to quantitative real-time polymerase chain reaction (PCR) by using the Light Cycler (Roche Diagnostics, Mannheim, Germany) and SYBR Green PCR Master Mix kit (Roche Diagnostics). Primer sequences (Sigma-Proligo, St Louis, MO) used for PCR of CIP2A were as follows: CIP2A forward, 5´-CTGGTGAGATAATCAG-CAATTT-3´ and CIP2A reverse, 5´-CGAAACATTCATCA-GACTTTTCA-3´. Transcript levels were normalized to levels of TATA-binding protein (TBP) or β-Actin expression, which were determined by PCR of the same samples using the following primers: TBP forward, 5´-GAATATAATCCCAAGCGGTTTG-3´, and TBP reverse, 5´-ACTTCACATCACAGCTCCCC-3´; Actin forward, 5´-CGAGCACAGAGCCTCGCCTTTGC-3´, and Actin reverse: 5´-CATAGGAATCCTTC TGACCCATG-3´.
Bioinformatics
Cancer cell line encyclopaedia (http://www.broadinstitute.org/ software/cprg/?q=node/11) was used to get the expression levels of JNK1 and JNK2 in HT1080 cells 22 . This is a resource which provides analysis and visualization of DNA copy number, mRNA expression, mutation data and more, for 1000 cancer cell lines.
Statistics
Student T-test was used obtain the statistical significance value using Graph Pad software.
Results

SP600125 inhibits CIP2A mRNA and protein expression in a time and concentration dependent manner in HT1080 cells
To determine the oncogenic signalling pathways that maybe involved in regulating CIP2A expression in human fibrosarcoma, HT1080 cells were treated with small molecule inhibitors for the p38 (SB203580; 20 µM), JNK (SP600125; 10 µM) and ERK (PD98058; 20 µM) signalling pathways. As previously observed in gastric cancer cells 17 , PD98058 reduced CIP2A mRNA and protein expression in HT1080 cells ( Figure 1A and B). Importantly, while SB203580 showed negligible effect, SP600125 potently inhibited CIP2A mRNA and protein expression in HT1080 ( Figure 1A and B) cells. Furthermore, inhibition of CIP2A protein expression by SP600125 was observed to be both time and concentration dependent ( Figure 1C and D).
Neither JNK1 nor JNK2 regulate CIP2A protein expression in HT1080 SP600125-mediated inhibition of CIP2A expression suggested the involvement of the c-Jun N-Terminal Kinases (JNKs) in regulation of CIP2A expression in HT1080 cells. Since the JNK3 isoform is well known to be neural-specific 23 , specific validated siRNAs against JNK1 and JNK2 isoforms were transfected into HT1080 cells and CIP2A expression estimated. Although, both JNK1 and JNK2 siRNAs reduced their target proteins (JNK1 and JNK2 respectively), there was no change in CIP2A protein expression with either of them individually ( Figure 2A To determine the oncogenic signalling pathways that may be involved ( Figure 2C ). Since the JNK2 isoform is expressed more than 10-fold higher than the JNK1 isoform in the HT1080 22 ( Figure 2D ) cell line we transfected two validated and specific siRNAs against JNK2. In addition, we also transfected the HT1080 cells with two different CIP2A siRNA as positive controls. In line with our previous observation ( Figure 2B and C) , the two different siRNAs for JNK2 knocked out JNK2 expression ( Figure 2E ), while CIP2A expression remained unaltered. Surprisingly, two different CIP2A siRNA, which worked well as positive controls, efficiently decreased JNK2 expression ( Figure 2E ).
Discussion
Even though small molecule inhibitors are an emerging therapeutic option against cancers, the specificity issues limit their potential to be used in clinics. They have been extensively used to study various cell signalling pathways. In particular SP600125 has been used to study the effect of c-Jun N-Terminal Kinases (JNKs) in various processes [24] [25] [26] . Our results suggest that even though we were able to see decrease in CIP2A expression in HT1080 cells on treatment with SP600125 (Figure 1) , at doses used previously to inhibit c-Jun NH 2 -terminal kinase (JNKs) activity 27,28
, we were not able to validate the findings using two different siRNAs specific to the JNK2 kinase ( Figure 2E) .
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No competing interests were disclosed. I thank Dr. Clark for his prompt and valuable comments on the manuscript. However, I would like to highlight Figures 2B, C and E wherein almost 100% knockdown of JNK2 kinase was achieved. In fact, two different siRNAs for JNK2 isoform, which is the isoform that is majorly expressed in HT1080 (Fig. 2D ) cells, completely abolished JNK2 expression leaving little room for the existence of residual JNK2 activity in these cells for maintaining CIP2A levels. Additionally, 10 fold higher expression of JNK2 isoform in comparison to the JNK1 isoform in Ht1080 cells (Fig 2D) , suggests it to be more relevant functionally.
"...the data presented in figure 2A show that JNK1 expression was suppressed by only 50% and the author failed to show the level of JNK1 expression in the experiment depicted in " figure 2C .
I thank Dr. Clark for this relevant observation. I have now attached the JNK1 levels from the experiment shown in Fig 2C as supplementary figure 1A with quantifications. As shown in the figure, despite complete knockdown of JNK1 in these cells, CIP2A levels remain almost unaltered, thereby re-emphasizing the fact that JNK1 does not regulate CIP2A expression in HT1080 cells. Complete knockdown of JNK1 also rules out the possibility of residual JNK1 activity driving CIP2A expression and the use of c-Jun as marker of JNK function in this experiment. With reference to SP600125, the concentrations used in Figure 1 have been demonstrated previously in several studies to inhibit JNK activity (p-Jun levels I thank Dr. Clark for sharing his expertise in the field and totally agree that structurally-unrelated kinase inhibitors have decreased off target effects and their use would definitely further confirm the negative findings. However, the main aim of this study is to highlight the un-specificity of SP600125 compound which has been used extensively as specific JNK inhibitor. In addition, using two different siRNAs (to overcome off-target effects due to one siRNA) that knock down JNK2 expression almost completely (Fig 2E) I thank Dr. Clark for highlighting the issue of siRNA specificity and totally agree that there are off-target effects that have to be ruled out with this approach. It is for this reason most journals and the general scientific community requests the use of two independent siRNAs for verifying the effects due to depletion of the target gene. Accordingly, as shown in Fig 2E, there have been two independent siRNAs against both JNK2 and CIP2A used which not only almost completely deplete their target proteins but also rule out the element of un-specificity which usually arises by the use of a single siRNA against the target protein.
Additionally, an independent study ( ) using microarray approach Niemelä 2012 et al., identified JNK2 as downstream target of CIP2A in HeLa cells, thereby lending further confidence to these findings. Moreover, as mentioned in the manuscript this finding surfaced just by chance as CIP2A siRNAs were being used as positive controls in the experiment. Additionally, I agree and have now further highlighted in the manuscript as well that CIP2A-mediated regulation of JNK2 would need further exploration. Finally, I would like to emphasize that the main aim of this study is to highlight that SP600125, concentrations at which it has been demonstrated to inhibit JNK activity, may also inhibit other kinases as highlighted by an elegant study previously (kinases that it inhibits have been listed in supplementary table 1). Interestingly, we recently identified CHK1 kinase (which is almost as sensitive as JNK to SP600125) as a positive regulator of CIP2A expression (Khanna et ). Therefore, to explore the possible role of CHK1 and other SP600125 sensitive , 2013 al. kinases in regulating CIP2A expression, we did a pilot screen and transfected HT1080 cells with 2 different siRNAs against CHK1 (Kinase almost as sensitive to SP600125 as JNK according to previously published study) and with siRNAs against CDK2 and DYRK1 (two other kinases that are more sensitive to SP600125 than JNK2). As shown in supplementary figure 1B, two different siRNAs against CHK1 decreased CIP2A expression as observed previously, while CDK2 and DYRK1 didn't change CIP2A expression. This 1.
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as observed previously, while CDK2 and DYRK1 didn't change CIP2A expression. This suggests that most likely the SP600125 kinase regulating CIP2A expression in HT1080 is CHK1, as observed in other cancers cells like prostate, breast, gastric and cervical cancers ( ). Khanna ., 2013 et al "Although the experiments are well performed, the study is incomplete and does not allow one to make a strong case for or against involvement of the JNKs in regulating CIP2A expression." I thank Dr. Clark for his positive and encouraging comments and hope that the my response, new data and changes in the text mitigate his previous concerns and are enough to conclude that there are un-specificity issues that may exist with SP600125, the small molecule inhibitor of JNK2 kinase as highlighted by the study.
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